Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014 Santhera Pharmaceuticals, 26 Nov 2013 Accessed on 2 Dec 2013 from http://www.santhera.com/index.php?docid=212&vid=&lang=en&newsdate=201311&newsid=1745645&newslang=en. CommentRecommendBookmarkWatch